ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2020

Abstract Number: 1577

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

Jeffrey Sarazin1, Ann Impens2, Nada Abdulaziz1, Stacey Anderson3, Leslie Fecher1, Christopher Lao1 and Elena Schiopu1, 1Michigan Medicine, Ann Arbor, MI, 2Midwestern University, Ann Arbor, IL, 3University of Michigan, Ann Arbor, MI

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Health Assessment Questionnaire (HAQ), Inflammation, Miscellaneous Rheumatic and Inflammatory Diseases, quality of life

Session Information

Date: Monday, November 9, 2020

Title: Immunological Complications of Therapy Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related adverse events (IRAEs), that resemble autoimmune diseases. Inflammatory arthritis (ICI-IA) has significant impact on function, but little is understood about these patterns of arthritis and the specific quality of life impairment.

Methods: We performed a retrospective review of patients at one academic center who experienced ICI-IA and required referral to a rheumatologist in the collaborative Oncology-Rheumatology clinic. All patients were evaluated and completed a Health Assessment Questionnaire Disability Index (HAQ-DI). The pattern of ICI-IA was classified by a single rheumatologist based on the arthritis pattern as: inflammatory symmetrical polyarthritis (RA-like, IA), polymyalgia rheumatica-like (PMR), seronegative spondyloarthritis-like (SpA) and exacerbation of osteoarthritis-like (OA). Demographics (gender, age, and race) and malignancy (type, IRAE, type of ICI) data was collected. HAQ-DI, pain and patient global activity (PGA) visual analogue scores were compared based of the type of inflammatory arthritis using average and mean scores.

Results: Our review included 30 patients with ICI-IA: 12 with IA, 4 with PMR, 3 with SpA and 11 with OA. As expected for this age group, a majority, specifically 23, had pre-existent degenerative joint disease (DJD) and 5 had inflammatory arthritis (1 with rheumatoid arthritis (RA), 2 with psoriatic arthritis (PsA), and 2 with gout). Most patients were male (23, 76.6%), and all were Caucasian. The malignancy data and type of ICI are in Table 2. In terms of the patient reported outcomes, the overall HAQ-DI score was 0.57 ± 0.47, indicating that there was little effect of these arthropathies on overall functionality. The pain visual analogue scale had an average score of 41.8 ± 31.4 mm and the Patient Global Assessment had an overall score of 25.6 ± 26.7 mm.

Conclusion: The overall results suggest that the PMR-like pattern of ICI-IA is the most impactful based on the total HAQ scores. In contrast, the pain scores are higher in the SpA group, followed by the IA group. The overall PGA is highest in the IA group, followed by the SpA group. Interestingly, the HAQ scores were lower than the reported average scores of degenerative (0.8) or inflammatory arthritis (1.2). Our sample sizes for the subgroups are currently too small to allow for further statistical analyses of association or subgroup comparisons.  Continued patient recruitment and further follow up will allow for understanding of the ICI-IA phenotypes will help understand and improve functionality and quality of life.

Table 1: Characteristics of ICI-IA patients broken down by ICI subtype.

Table 2: The averages of each HAQ-DI domain for each subset of inflammatory arthritis, in addition to the means for pain VAS and PGA


Disclosure: J. Sarazin, None; A. Impens, None; N. Abdulaziz, None; S. Anderson, None; L. Fecher, None; C. Lao, None; E. Schiopu, Octapharma, 2.

To cite this abstract in AMA style:

Sarazin J, Impens A, Abdulaziz N, Anderson S, Fecher L, Lao C, Schiopu E. Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/immune-checkpoint-inhibitor-induced-inflammatory-arthritis-impact-on-function-and-patient-reported-quality-of-life-measures-varies-depending-on-pattern-of-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-checkpoint-inhibitor-induced-inflammatory-arthritis-impact-on-function-and-patient-reported-quality-of-life-measures-varies-depending-on-pattern-of-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology